Vitae Pharmaceuticals Inc. (NASDAQ:VTAE)’s share price fell 2.8% during trading on Tuesday . The company traded as low as $9.93 and last traded at $10.05, with a volume of 57,829 shares. The stock had previously closed at $10.34.

A number of research firms recently commented on VTAE. Zacks Investment Research cut shares of Vitae Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Vitae Pharmaceuticals in a research note on Friday, June 10th. Wedbush reaffirmed an “outperform” rating and set a $23.00 price target on shares of Vitae Pharmaceuticals in a research note on Wednesday, May 25th. Finally, BMO Capital Markets began coverage on shares of Vitae Pharmaceuticals in a research note on Monday, April 11th. They set an “outperform” rating and a $15.00 price target for the company. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $16.65.

The stock’s 50 day moving average is $10.40 and its 200-day moving average is $8.94. The company’s market capitalization is $289.28 million.

Vitae Pharmaceuticals (NASDAQ:VTAE) last issued its earnings results on Tuesday, May 10th. The company reported ($0.44) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.51) by $0.07. The company earned $0.05 million during the quarter. During the same quarter in the previous year, the company earned ($0.47) earnings per share. Vitae Pharmaceuticals’s revenue for the quarter was down 66.7% compared to the same quarter last year. Equities analysts anticipate that Vitae Pharmaceuticals Inc. will post ($1.74) earnings per share for the current year.

A hedge fund recently bought a new stake in Vitae Pharmaceuticals stock. Dimensional Fund Advisors LP bought a new stake in Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm bought 73,607 shares of the company’s stock, valued at approximately $1,332,000. Dimensional Fund Advisors LP owned about 0.34% of Vitae Pharmaceuticals as of its most recent SEC filing.

Vitae Pharmaceuticals, Inc is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.